Naltrexone-Bupropion Combination

Phase 3Small molecule

Naltrexone-Bupropion Combination is one of 78 small molecule programs targeting Weight loss. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossRecruiting

ObesityActive, not recruiting

Cardiovascular EventsRecruiting

Weight LossPhase 3

Recruiting

ObesityPhase 3

Active, not recruiting

Cardiovascular EventsPhase 3

Recruiting

Competition

Competitive Landscape

176 competitors in Obesity

#DrugCompanyPhaseTrials

Cagrilintide

Novo Nordisk

Phase 3

9 2

Decadron

AAspen Global Incorporated

Phase 3

2 3

Synthroid

IInstitut Jerome Lejeune

Phase 3

1 4

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 5

Cagrisema

Novo Nordisk

Phase 3

5 6

Eloralintide

Eli Lilly

Phase 3

13 7

Naltrexone-Bupropion Combination

CCurrax Pharmaceuticals

Phase 3

2 8

PF-08653944

Pfizer

Phase 3

6 9

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 10

Actemra

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Weight Loss

NCT05919797

Q2 2028

ApprovedActive, not recruiting

Obesity

NCT06854614

Q3 2029

Post-ApprovalRecruiting

Cardiovascular Events

NCT06098079

Clinical

Trials by Indication[1]

Obesity2 trials

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Unknown status·NNational and Kapodistrian University of Athens·Phase 4·NCT04575194·40 enrolled

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

Active, not recruiting·TThe Cleveland Clinic·Approved·NCT06854614·150 enrolled

Bariatric Surgery1 trial

Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

Unknown status·ZZuyderland Medisch Centrum·Phase 4·NCT04902625·116 enrolled

Cardiovascular Events1 trial

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting·CCurrax Pharmaceuticals·Phase 4·NCT06098079·8,600 enrolled

Weight loss1 trial

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Recruiting·—·Phase 4·NCT05919797·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Naltrexone-Bupropion Combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Naltrexone-Bupropion Combination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Naltrexone-Bupropion Combination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Currax Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCurrax Pharmaceuticals

Naltrexone-Bupropion Combination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2029

Trials by Indication[1]

Obesity2 trials

Bariatric Surgery1 trial

Cardiovascular Events1 trial

Weight loss1 trial

References

Drug Info

Quick Facts

Related News